Measure Description
The percentage of patients 5-64 years of age during the measurement year who were identified as having persistent asthma and were dispensed appropriate medications that they remained on for at least 75% of their treatment period
Instructions
This measure is to be submitted a minimum of once per performance period for patients with a diagnosis of persistent asthma seen during the performance period. This measure may be submitted by Merit-based Incentive Payment System (MIPS) eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.
Measure Submission Type:
The listed denominator criteria are used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions as allowed by the measure. The quality-data codes listed do not need to be submitted by MIPS eligible clinicians, groups, or third party intermediaries that utilize this modality for submissions; however, these codes may be submitted for those third party intermediaries that utilize Medicare Part B claims data. For more information regarding Application Programming Interface (API), please refer to the Quality Payment Program (QPP) website.
Denominator
Patients 5-64 years of age with persistent asthma and a visit during the measurement period
DENOMINATOR NOTE: *Signifies that this CPT Category I code is a non-covered service under the Medicare Part B Physician Fee Schedule (PFS). These non-covered services should be counted in the denominator population for MIPS CQMs.
Denominator Criteria (Eligible Cases):
Patients aged 5-64 years on date of encounter
AND
Diagnosis for persistent asthma (ICD-10-CM): J45.30, J45.31, J45.32, J45.40, J45.41, J45.42, J45.50, J45.51, J45.52
AND
Patient encounter during the performance period (CPT): 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350, 99381*, 99382*, 99383*, 99384*, 99385*, 99386*, 99387*, 99391*, 99392*, 99393*, 99394*, 99395*, 99396*, 99397*
AND NOT
DENOMINATOR EXCLUSIONS:
Diagnosis of COPD, Emphysema, Obstructive Chronic Bronchitis, Chronic Respiratory Conditions Due to Fumes/Vapors, Cystic Fibrosis, or Acute Respiratory Failure any time during the patient’s history through the end of the measurement year: E84.0, E84.11, E84.19, E84.8, E84.9, J43.0, J43.1, J43.2, J43.8, J43.9, J44.0, J44.1, J44.9, J68.4, J96.00, J96.01, J96.02, J96.20, J96.21, J96.22, J98.2, J98.3
OR
Any patients who had no asthma controller medications dispensed during the measurement year: G9808
OR
Patients who use hospice services any time during the measurement period: G9809
Numerator
The number of patients who achieved a proportion of days (PDC) of at least 75% for their asthma controller medications during the measurement year
Definition:
PDC – The proportion of days covered by at least one asthma controller medication prescription, divided by the number of days in the treatment period. The treatment period is the period of time beginning on the earliest prescription dispensing date for any asthma controller medication during the measurement year through the last day of the measurement year.
Asthma Controller Medications
Description | Prescriptions | ||
Antiasthmatic combinations | Dyphylline-guaifenesin | Guaifenesin-theophylline | |
Antibody inhibitor | Omalizumab | ||
Inhaled steroid combinations | Budesonide-formoterol | Fluticasone-salmeterol | Mometasone-formoterol |
Inhaled corticosteroids | Beclomethasone Budesonide | Ciclesonide | Fluticasone CFC free Mometasone |
Leukotriene modifiers | Montelukast | Zafirlukast | Zileuton |
Mast cell stabilizers | Cromolyn | ||
Methylxanthines | Aminophylline | Dyphylline | Theophylline |
Anti-interleukin-5 | Mepolizumab | Reslizumab |
Numerator Options:
Performance Met: Patient achieved a PDC of at least 75% for their asthma controller medication (G9810)
OR
Performance Not Met: Patient did not achieve a PDC of at least 75% for their asthma controller medication (G9811)